A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2016
At a glance
- Drugs Ridaforolimus (Primary)
- Indications CNS cancer; Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Merck & Co
- 12 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2010 Results will be presented as the Americal Society of Clinical Oncology Annual Meeting 2010, according to an Ariad Pharmaceuticals media release.
- 19 Mar 2010 Planned end date changed from 1 Jun 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.